Search
Hovione Capacity Expansion
Hovione is Growing
Hovione is recognized as a Top Employer 2023
This certification is a recognition of Hovione´s resolve to put people first, and a validation that the investment in HR excellence is delivering.
Hovione launches new website for the Chinese Market
Hovione is closer to its customers with a new website in Mandarin
Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Jean-Luc Herbeaux to become Hovione CEO
Hovione today announced the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective 1st April 2022
Hovione strengthens its global position as a top employer for the third consecutive year
Hovione has once again solidified its position as a top employer.
Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million
Business Wire, September 23, 2020